NVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novo Nordisk (NVO) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown some positive developments in its diabetes treatments, the stock faces significant headwinds, including analyst downgrades, reduced price targets, and concerns about long-term growth. The technical indicators and options data suggest a neutral to slightly bearish sentiment, and the lack of strong proprietary trading signals further supports a cautious approach.
The MACD histogram is positive at 0.336, indicating mild bullish momentum, but it is contracting. RSI is neutral at 39.64, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. The stock is trading near its support level (S1: 37.571), with resistance at R1: 40.978.
Hedge funds have increased their buying activity by 112.57% in the last quarter.
Multiple analyst downgrades and reduced price targets reflect concerns about the company's growth trajectory, including underperformance of weight loss drugs in the U.S. and potential margin contraction. The stock has a historical trend of declining in the short to medium term, with a 90% probability of a -1.33% drop in the next week and -3.01% in the next month.
In Q4 2025, revenue grew by 0.69% YoY, net income increased by 3.84% YoY, and EPS rose by 3.30% YoY. However, gross margin declined by -4.65% YoY to 80.86, indicating potential cost pressures.
Recent analyst ratings are predominantly negative, with several downgrades and price target reductions. Citi, HSBC, TD Cowen, and Goldman Sachs have all lowered their price targets, citing concerns about growth, drug performance, and macroeconomic risks.
